Prolongation of xenograft survival by soluble complement receptor type 1 and antithrombin-III combination therapy.
Fujiwara
I
I
Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Nakajima
H
H
Arakawa
K
K
Akioka
K
K
Takeshita
K
K
Oka
T
T
D000818:Animals; D000990:Antithrombin III / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D006168:Guinea Pigs; D016027:Heart Transplantation / Q000276:immunology / Q000502:physiology*; D007165:Immunosuppression Therapy / Q000379:methods; D008297:Male; D011453:Prostaglandins / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains; D011951:Receptors, Complement / Q000276:immunology*; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology / Q000502:physiology*
D011453:Prostaglandins; D011951:Receptors, Complement; D000990:Antithrombin III